Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
Zacks.com on MSN2d
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCCExelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
The partners will focus on evaluating Exelixis’ zanzalintinib, a tyrosine kinase inhibitor, alongside MSD's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase III trial for head and neck ...
Exelixis and Merck & Co. have inked a deal to study Exelixis' investigational drug zanzalintinib in combination with a pair of Merck's cancer drugs. The companies in Wednesday said the agreement ...
Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the development of its pipeline candidate, zanzalintinib. Zanzalintinib ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback